Shares in Summit plc gained 26 percent Tuesday on news of a collaboration agreement on the company's Seglin technology with Bristol-Myers Squibb Co. (BMS) that could be worth as much as $300 million in research, development and regulatory milestones. Read More
LONDON – Detailed analysis of genes associated with autoimmune diseases has identified three new regions where genetic variation plays a role in determining the risk of the autoimmune liver disease called primary biliary cirrhosis (PBC). Read More
LONDON – TauRx Therapeutics Ltd. announced the start of a 180-patient Phase III trial of its tau aggregation inhibitor, LMTX, in Pick's disease, an early onset form of dementia that shows similar characteristics to Alzheimer's disease. Read More
LONDON – Takeda Pharmaceutical Co Ltd. is celebrating the completion of its €75 million (US$96 million) manufacturing facility in Russia, becoming one of the first international pharmaceutical companies to put down roots in that important emerging market. Read More
Karus Therapeutics Ltd. banked $7.6 million, the first tranche of a Series B round that is intended to enable the company to take its two lead programs through human proof-of-concept studies. Read More
With two key value inflection points approaching, Biotie Therapies Oy did some advance corporate housekeeping by adding €30 million (US$38.3 million) to its coffers, to strengthen its position for any upcoming licensing negotiations. Read More
LONDON – Symphogen A/S has handed Merck KGaA worldwide exclusive rights to its Phase II cancer antibody product, Sym004, in a deal with a potential value of €500 million (US$631.6 million). Read More
F2G Ltd., of Manchester, UK, will use a new $30 million equity financing round to jump a lead candidate from its F3 series of preclinical compounds into first-in-man studies. Read More
• Compugen Ltd., of Tel Aviv, Israel, said mode-of-action studies on protein drug candidate CGEN-15001 demonstrated active suppression of pathogenic immune responses and reestablishment of immune balance by increasing anti-inflammatory mediators and promoting inducible regulatory T cells, considered a promising approach to treat autoimmune disease and cancer. Read More
